HOXA5 as a Dual Modulator of Tumor Biology in Endometrial Cancer

<b>Background/Objectives</b>: Endometrial cancer (EC) is the most prevalent gynecological malignancy, with increasing incidence and mortality. HOXA5, a developmental transcription factor, has been linked to prognosis in various cancers, but its role in EC remains unclear. This study aimed to evaluate the prognostic potential of HOXA5 in EC and to explore its association with common tumor-related proteins. <b>Methods</b>: We analyzed 75 EC tissue samples using immunohistochemistry to evaluate HOXA5 expression and its association with clinicopathological features and tumor-related biomarkers, including Ki-67, CD31, and fibronectin. Statistical analyses included logistic regression and Kaplan-Meier survival analysis. <b>Results</b>: High HOXA5 expression was significantly associated with elevated Ki-67 levels (<i>p</i> = 0.001) but paradoxically correlated with improved overall survival (<i>p</i> = 0.026). CD31 and fibronectin levels were significantly lower in the high-HOXA5 group (<i>p</i> = 0.007 and <i>p</i> = 0.001, respectively), suggesting reduced angiogenic and invasive potential. However, neither marker remained significant in multivariable analysis. <b>Conclusions</b>: HOXA5 may exert a dual role in EC by promoting proliferation while limiting tumor progression via suppression of angiogenesis and matrix remodeling. It holds potential as a prognostic biomarker and therapeutic target.